Ina Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 15-12-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.93 Cr
as on 15-12-2024
- Revenue 17.78%
(FY 2022)
- Profit -33.23%
(FY 2022)
- Ebitda 24.63%
(FY 2022)
- Net Worth 26.23%
(FY 2022)
- Total Assets 58.91%
(FY 2022)
About Ina Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹6.93 Cr.
Rajeshwari Golla and China Golla serve as directors at the Company.
- CIN/LLPIN
U24100TG2018PTC127607
- Company No.
127607
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ina Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
China Golla  | Managing Director | 09-Jun-2019 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajeshwari Golla | Director | 12-Oct-2018 | Current |
Financial Performance of Ina Pharmaceuticals.
Ina Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 17.78% increase. The company also saw a substantial fall in profitability, with a 33.23% decrease in profit. The company's net worth Soared by an impressive increase of 26.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ina Pharmaceuticals?
In 2022, Ina Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ajas Pharma Private LimitedActive 8 months 17 daysRajeshwari Golla and China Golla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Jun 2020 | ₹6.93 Cr | Open |
How Many Employees Work at Ina Pharmaceuticals?
Ina Pharmaceuticals has a workforce of 12 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ina Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ina Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
